Anti-CCR8 antibody therapy, targeting tumor-infiltrating CCR8+ Tregs, has the potential to restore the function of CD4+ Th and CD8+ T cells in CRC, thereby inducing antitumor immunity (106). The gene discussed is CCR8; the disease is colorectal carcinoma.